Intercept Pharmaceuticals | Passivo Circulante



Passivo Circulante Alterar Data
Acadia Pharmaceuticals USD 356.58M 26.56M 2025-09
Alnylam Pharmaceuticals USD 1.47B 89.13M 2025-12
Amarin USD 182.23M 3.71M 2025-09
Amgen USD 25.49B 3.7B 2025-12
Arrowhead Research USD 347.42M 151.94M 2025-12
AstraZeneca USD 30.62B 3.44B 2025-12
Biogen USD 3.35B 59.4M 2025-12
Bristol-Myers Squibb USD 28.14B 608M 2025-09
Eli Lilly USD 35.23B 4.91B 2025-12
Enanta Pharmaceuticals USD 44.73M 3.83M 2025-12
Esperion Therapeutics USD 359.03M 60.24M 2025-09
Galectin Therapeutics USD 14.62M 1.98M 2024-06
Gilead Sciences USD 11.81B 485M 2025-12
GlaxoSmithKline GBP 21.39B 57M 2025-12
Incyte USD 1.52B 176.44M 2025-12
Ionis Pharmaceuticals USD 903.46M 6.22M 2025-09
Moderna USD 1.99B 306M 2025-12
Neurocrine Biosciences USD 743.4M 105.4M 2025-12
Novartis USD 32B 286M 2025-09
PTC Therapeutics USD 866.24M 238.44M 2025-09
Regeneron Pharmaceuticals USD 4.37B 56.7M 2025-12
Sangamo BioSciences USD 47.66M 1.9M 2025-06
Sarepta Therapeutics USD 921.42M 1.48M 2025-09
Vertex Pharmaceuticals USD 3.86B 614.1M 2025-12


Intercept Pharmaceuticals Passivo Circulante - Valores atuais, dados históricos, previsões, estatísticas, gráficos e calendário econômico - Feb 2026.